Portal de Periódicos da CAPES

Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia

2019; Ferrata Storti Foundation; Volume: 104; Issue: 8 Linguagem: Inglês

10.3324/haematol.2019.217141

1592-8721

Junko Yamaguchi, Takahiro Fujino, Reiko Isa, Daichi Nishiyama, Saeko Kuwahara‐Ota, Yuka Kawaji, Taku Tsukamoto, Yoshiaki Chinen, Yuji Shimura, Tsutomu Kobayashi, Shigeo Horiike, Kei Kohno, Shigeo Nakamura, Junya Kuroda,

Chronic Lymphocytic Leukemia Research

Imatinib mesylate (IM) is a first generation ATP-competitive selective inhibitor for tyrosine kinases (TK) such as ABL, ARG, PDGFRα and b, and c-KIT.[1][1] While use of IM has markedly improved treatment outcomes of Philadelphia chromosome (Ph)-positive leukemias, including chronic myeloid leukemia